<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-14T21:32:46Z</responseDate>
  <request identifier="oai:figshare.com:article/33717760" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33717760</identifier>
        <datestamp>2026-09-14T04:31:23Z</datestamp>
        <setSpec>category_696</setSpec>
        <setSpec>portal_316</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Supplementary file 1_Astragalus polysaccharide antagonized anti PD-1 efficacy in melanoma through inhibiting JAK-STAT1/CIITA and TLR/NF-κB signaling.docx</dc:title>
          <dc:creator>Ruilong Wang (15301816)</dc:creator>
          <dc:creator>Qiao Li (571252)</dc:creator>
          <dc:creator>Mengguo Liu (6628241)</dc:creator>
          <dc:creator>Jinshu Yu (2651383)</dc:creator>
          <dc:creator>Min Peng (44784)</dc:creator>
          <dc:creator>Xiaohong Deng (626496)</dc:creator>
          <dc:creator>Rui Lei (7536488)</dc:creator>
          <dc:creator>Xiao Liu (65413)</dc:creator>
          <dc:creator>Zhihao Li (359073)</dc:creator>
          <dc:creator>Hiochon Leong (24125676)</dc:creator>
          <dc:creator>Jie Ren (176083)</dc:creator>
          <dc:creator>Jinfeng Wu (608446)</dc:creator>
          <dc:subject>Genetic Immunology</dc:subject>
          <dc:subject>anti PD-1</dc:subject>
          <dc:subject>astragalus polysaccharide</dc:subject>
          <dc:subject>JAK-STAT1</dc:subject>
          <dc:subject>melanoma</dc:subject>
          <dc:subject>TLR</dc:subject>
          <dc:description>Objective&lt;p&gt;Advanced melanoma remains a major clinical challenge due to resistance to immune checkpoint inhibitors (ICIs, e.g., anti PD-1). Astragalus Polysaccharide (APS) is a clinically approved immunomodulator for cancer treatment. However, its interaction with anti PD-1 remains largely unknown. This study aims to explore the efficacy and underlying mechanism of APS combined with anti PD-1 in melanoma.&lt;/p&gt;Methods&lt;p&gt;For in vivo studies, the anti-tumor effect of APS combined with anti PD-1 was evaluated in a B16-OVA melanoma mouse model. For mechanism exploration, immunohistochemistry, flow cytometry, ELISA, PCR array, qRT-PCR, Western blotting and confocal microscopy were employed to detect tumor immune microenvironment changes and related signaling pathway activation.&lt;/p&gt;Results&lt;p&gt;Unexpectedly, APS significantly antagonized the anti-tumor efficacy of anti PD-1 in melanoma mice. APS reversed anti PD-1-induced infiltration of CD4&lt;sup&gt;+&lt;/sup&gt; T cells, CD8&lt;sup&gt;+&lt;/sup&gt; T cells and dendritic cells (DCs) in the tumor microenvironment, and impaired DC maturation and CD4&lt;sup&gt;+&lt;/sup&gt; T cell activation. Mechanistically, APS significantly inhibited JAK-STAT1 signaling, downregulated MHCII master regulator CIITA, and subsequently reduced MHCII expression. Meanwhile, APS markedly suppressed TLR signaling and attenuated NF-κB mediated inflammatory responses in B16-OVA melanoma cells and DCs.&lt;/p&gt;Conclusion&lt;p&gt;APS antagonized anti PD-1 efficacy by inducing an immunosuppressive microenvironment via dual inhibition of JAK-STAT1/CIITA signaling and TLR/NF-κB signaling. This study suggests that the combination of natural polysaccharides and ICIs may warrant caution, although further studies are needed to validate these findings and determine their clinical relevance.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-14T04:31:23Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.3389/fimmu.2026.1947786.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Supplementary_file_1_Astragalus_polysaccharide_antagonized_anti_PD-1_efficacy_in_melanoma_through_inhibiting_JAK-STAT1_CIITA_and_TLR_NF-_B_signaling_docx/33717760</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
